Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Several juxtaposed images of different patients with different responses to the cancer treatment

Study with mint Lesion™ compares the Efficacy of SIRT and CS-PHP in Uveal Melanoma with Hepatic Metastasis

A study conducted by researchers at University Hospital Tuebingen retrospectively compared two liver-targeted therapies for uveal melanoma patients with liver metastases. The results showed that Chemosaturation-Percutaneous Hepatic Perfusion (CS-PHP) had significantly longer overall survival (516 days) compared to Transarterial Radioembolization (SIRT) (300.5 days).

mint Lesion™ was used to assess the treatment efficacy in line with the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The study observed that the disease control rate, which includes Complete Response (CR), Partial Response (PR), and Stable Disease (SD), was 18% for SIRT and 30% for CS-PHP.

These findings highlight the need for further research and prospective randomized trials to optimize liver-targeted treatment strategies and address the challenges faced by patients with this condition. Learn more.

Clinical Trials Clinical Routine Standardized Reading Procedures Therapy Response Assessment Data Collection RECIST Research with mint

Related Resources

Related Resources

A picture of workshop participants next to a positive review for the ESOI-EORTC RECIST Workshop in Munich

ESOI-EORTC Workshop on Imaging in Assessing Response to Cancer Therapy - A Participant's Perspective

Following the conclusion of the ESOI-EORTC Workshop on Imaging in Assessing Response to Cancer Therapy in Munich, we were keen to gather feedback…

A diagram and a CT scan visualizing tumor growth rate in patients with refractory or relapsed lymphoma

Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients

A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics…

Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…